VIVA and The VEINS are now accepting abstracts for the 2025 Late-Breaking Clinical Trial sessions. A limited number of abstracts will be accepted for presentation, offering attendees a first look at the latest practice-changing data.
Accepted trials will be presented on November 2 (The VEINS) and November 3 - 4 (VIVA). Each presentation will be followed by an interactive discussion and audience Q&A, led by a panel of renowned experts. Don’t miss your chance to contribute to the conversation driving the next era of vascular innovation.
The 2025 abstract submission portal is now open. Access here.
The abstract submission deadline is Thursday, August 7, at 5pm PT.
Research must be original and may not have been presented prior to VIVA or The VEINS 2025. Any research that is presented ahead of the conferences will be removed from the program.
Abstracts must be submitted for VIVA OR The VEINS, but not both. In select circumstances, the review committee may determine that your abstract is more appropriate for a different session or conference than you
originally submitted.
Abstract submissions should address areas of endovascular medicine or intervention and can report the results of basic science investigations as well as clinical or pre-clinical studies.
Abstracts must include:
Submissions will be reviewed after the August 7 deadline. Abstracts will be evaluated and scored based on the following criteria:
Notice of acceptance or rejection will be sent the week of August 25. Subsequent communication will provide specifics about submitting the presentation and the date and time of the presentation.
If you have questions please contact Brita Thorne via e-mail: abstracts@viva-foundation.org
